热门资讯> 正文
Lantheus收购Meiltero科技公司，获得阿尔茨海默氏症成像剂候选产品
2024-07-16 03:50
- Lantheus Holdings (NASDAQ:LNTH) has acquired Meilleur Technologies, giving it the phase 3 ß amyloid PET imaging agent, NAV-4694 (F18-flutafuranol), for use in the diagnosis and treatment of Alzheimer's.
- Lantheus already has another PET imaging agent candidate, MK-6240 (florquinitau), which targets tau tangles in phase 1.
- Lantheus will make an upfront payment, and Meilleur is eligible for milestone payments. Specifics were not disclosed.
More on Lantheus
- Lantheus' Strategic Advantage Amplified By New CMS Payment Refinements (Rating Upgrade)
- Leading The Growth Of Radiopharmaceuticals: Mini Deep Dive On Lantheus
- Lantheus Holdings: Powerful First Quarter
- Lantheus hits 52-week high on Medicare proposal (update)
- Lantheus acquires global rights to Life Molecular's drug for prostate and breast cancers
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
